1887

Abstract

We investigated neutralizing antibodies to human papillomavirus type 16 (HPV-16) in serum and cervical washes from 84 women with normal cytology or cervical disease. Serum neutralizing antibodies were detected in 78 % of women infected at the cervix with HPV-16, compared with 35 % (=0.002) of women infected with HPV-16-related types (9 HPV types), 14 % (<0.0001) of women infected with HPV-16 non-related types and none of HPV-uninfected women. A significant correlation between HPV-16 infection and serum HPV-16-neutralizing antibodies was observed ( =0.97; =0.032). Cervical neutralizing antibodies were detected in 38 % of women with HPV-16 infection and in 17 % of women infected with the HPV-16-related type HPV-31. Cervical neutralizing antibodies correlated with HPV-16 infection ( =0.95; =0.08), but not with cervical disease. Serum and cervical HPV-16 antibody responses were not affected significantly by human immunodeficiency virus type 1 infection. In conclusion, serum and cervical HPV-16-neutralizing antibodies were found to correlate with HPV-16 infection, but not with cervical disease.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83458-0
2008-04-01
2019-11-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/4/910.html?itemId=/content/journal/jgv/10.1099/vir.0.83458-0&mimeType=html&fmt=ahah

References

  1. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M. & Shah, K. V. ( 2002; ). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55, 244–265.[CrossRef]
    [Google Scholar]
  2. de Gruijl, T. D., Bontkes, H. J., Walboomers, J. M. M., Coursaget, P., Stukart, M. J., Dupuy, C., Kueter, E., Verheijen, R. H. M., Helmerhorst, T. J. M. & other authors ( 1999; ). Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 80, 399–408.
    [Google Scholar]
  3. Gross, G. & Pfister, H. ( 2004; ). Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 193, 35–44.[CrossRef]
    [Google Scholar]
  4. Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A. B., Romonowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Clemens, S. A. C. & other authors ( 2006; ). Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247–1255.[CrossRef]
    [Google Scholar]
  5. Kawana, K., Yasugi, T., Kanda, T., Kawana, Y., Hirai, Y., Yoshikawa, H. & Taketani, Y. ( 2002; ). Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun 296, 102–105.[CrossRef]
    [Google Scholar]
  6. Lowy, D. R. & Schiller, J. T. ( 2006; ). Prophylactic human papillomavirus vaccines. J Clin Invest 116, 1167–1173.[CrossRef]
    [Google Scholar]
  7. Marais, D., Rose, R. C. & Williamson, A. L. ( 1997; ). Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol 51, 126–131.[CrossRef]
    [Google Scholar]
  8. Marais, D. J., Best, J. M., Rose, R. C., Keating, P., Soeters, R., Denny, L., Dehaeck, C. M. C., Nevin, J., Kay, P. & other authors ( 2001; ). Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia 1. J Med Virol 65, 149–154.[CrossRef]
    [Google Scholar]
  9. Marais, D. J., Sampson, C., Jeftha, A., Dhaya, D., Passmore, J.-A. S., Denny, L., Rybicki, E. P., Van Der Walt, E., Stephen, L. X. G. & Williamson, A.-L. ( 2006; ). More men than women make mucosal IgA antibodies to human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis 6, 1471
    [Google Scholar]
  10. Mqoqi, N., Kellet, P., Sitas, F. & Musa, J. ( 2004; ). Incidence of Histologically Diagnosed Cancer in South Africa, 1998–1999. Johannesburg: National Cancer Registry of South Africa.
  11. Pagliusi, S. R., Dillner, J., Pawlita, M., Quint, W. G. V., Wheeler, C. M. & Ferguson, M. ( 2006; ). Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays – an update. Vaccine 24, S193–200.[CrossRef]
    [Google Scholar]
  12. Pastrana, D. V., Buck, C. B., Pang, Y. Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Kjaer, S. K., Lowy, D. R. & Schiller, J. T. ( 2004; ). Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205–216.[CrossRef]
    [Google Scholar]
  13. Rudin, A., Johansson, E. L., Bergquist, C. & Holmgren, J. ( 1998; ). Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 66, 3390–3396.
    [Google Scholar]
  14. Sonnex, C. ( 1998; ). Influence of ovarian hormones on urogenital infection. Sex Transm Infect 74, 11–19.[CrossRef]
    [Google Scholar]
  15. Viscidi, R. P., Ahdieh-Grant, L., Clayman, B., Fox, K., Massad, L. S., Cu-Uvin, S., Shah, K. V., Anastos, K. M., Squires, K. E. & other authors ( 2003; ). Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 187, 194–205.[CrossRef]
    [Google Scholar]
  16. Viscidi, R. P., Snyder, B., Cu-Uvin, S., Hogan, J. W., Clayman, B., Klein, R. S., Sobel, J. & Shah, K. V. ( 2005; ). Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14, 283–288.
    [Google Scholar]
  17. Walboomers, J. M. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J. F., Peto, J., Meijer, C. J. L. M. & Munoz, N. ( 1999; ). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12–19.[CrossRef]
    [Google Scholar]
  18. White, W. I., Wilson, S. D., Bonnez, W., Rose, R. C., Koenig, S. & Suzich, J. A. ( 1998; ). In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 72, 959–964.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83458-0
Loading
/content/journal/jgv/10.1099/vir.0.83458-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error